Business
IRIDEX Launches Revised MicroPulse P3® Device for Glaucoma
MOUNTAIN VIEW, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products
About this update from Iridex Corporation
[{"type":"text","content":"MOUNTAIN VIEW, Calif., Feb. 26, 2020 (GLOBE NEWSWIRE) -- IRIDEX Corporation (NASDAQ: IRIX), a provider of innovative ophthalmic laser-based medical products for the treatment of glaucoma and retinal diseases, announced today the introduction of the second generation of the MicroPulse P3® Device, which has been redesigned to deliver greater stability, visualization, coupling, and fit.\n “The revised MicroPulse P3 Device is intuitive and easy to use. The design delivers energy in a much more consistent fashion and allows for very stable contact on the sclera,” said Dr. Brian A. Francis, Associate Professor of Ophthalmology at the Doheny Eye Institute, Keck School of Medicine, University of Southern California. “This device offers myself and my patients a treatment paradigm which can be introduced prior to, in conjunction with and following all other glaucoma treatment options, making it a very versatile tool in my practice.” The new MicroPulse P3 Device features a number of design improvements: Recessed fiber tip with added fluid channel to enable consistent fiber immersion in fluid during treatment to improve light coupling to the tissue.Concave “scleral-matching” footplate plate to improve stability.“Limbal-matching” footplate curvature added to better identify the orientation and placement of the device.Reduced footplate size for easier placement in eyes.Elongated stem to improve visualization of the treatment area. “The launch of our revised MicroPulse P3 Device represents an important step forward in simplifying our unique non-incisional glaucoma therapy. We are pleased with the initial physician users’ positive response to the product improvements,” said David Bruce, CEO of IRIDEX. “We anticipate these ease of use improvements will lead to greater physician confidence and adoption.” The MicroPulse P3 Device is used by physicians to perform MicroPulse® Transscleral Laser Therapy (TLT), which is a non-incisional, laser-energy procedure delivering substantial reduction in intraocular pressure suitable for a broad range of glaucoma patients. More than 120,000 patients have been treated in over 60 countries with the original version of the MicroPulse P3 Device. At the American Glaucoma Society annual meeting taking place in Washington, DC on February 27-29, 2020, IRIDEX will host “Meet the MicroPulse TLT Experts” sessions Thursda...